GOSS Gossamer Bio, Inc. Insider Trading

Director Milligan Sandra bought 26,050 shares of GOSS at $1.92, 81.4% increase in holdings, as stock rises 68.1% over 90 days from unprofitable biotech.

Director Milligan Sandra acquired 26,050 shares at $1.92 on 2025-08-19, expanding her stake by 81.4% from 32,000 to 58,050 shares for a total of $50,016.00. This accumulation is materially sized and follows a prior buy at this ticker on 2023-11-15 that returned +20.2% over 90 days. The timing is notable: the stock has appreciated 68.1% over the past 90 days and currently trades at $1.95, within 10.1% of its 52-week high. However, the company remains unprofitable with a net loss of $38,273,000.00 against quarterly revenue of $11,489,000.00, placing the transaction in a financially distressed biotech context where price momentum may not align with underlying business performance. The director's prior transaction at this ticker showed favorable 90-day returns, establishing a pattern of well-timed entry points, though the current fundamental picture—significant operating losses—warrants scrutiny of whether the recent stock appreciation reflects technical momentum or improved business prospects.

Hasnain Faheem (CEO) bought 372,000 GOSS shares at $0.67; cluster pattern with 2 other insiders also buying within 14 days

CEO Hasnain Faheem purchased 372,000 shares (372.0K shares) at $0.67, increasing his holdings from 5,036,073 shares to 5,408,073 shares (+7.4% increase). The company is unprofitable with a net income of $-41,928,000.00, and the stock trades at $0.83, down 54.4% from its 52-week high of $1.82 but up 33.9% over the past 30 days. This buy occurs within a cluster pattern: 2 other insiders also purchased shares within the past 14 days. Faheem's cross-ticker insider history shows 1 prior buy with an average 90-day return of +100.6% (100% win rate), though that track record spans multiple companies and may not reflect outcomes specific to GOSS. The filing warrants examination of whether the CEO's purchase reflects information about turnaround potential or is a routine holding consolidation.

CCO Smith Robert Paul JR bought 25,000 shares of GOSS at $0.60; stock down -57.8% over 90 days from unprofitable company.

Chief Commercial Officer Robert Paul Smith JR purchased 25,000 shares at $0.60 on 2024-06-17, establishing his first position in Gossamer Bio. The transaction occurred while the company reported net income of $-41.9M and the stock has declined -57.8% over the prior 90 days, trading at $0.57 (current), down -68.7% from its 52-week high of $1.82. The purchase represents a 25.0K share new position at a price 5% above current market levels, suggesting the executive initiated or increased commitment despite significant recent losses and negative profitability.

COO/CFO Bryan Giraudo buys 100,000 GOSS shares at $0.59; stock now $0.57, down 57.8% in 90 days amid -$41.9M net loss.

Bryan Giraudo, COO/CFO of Gossamer Bio, purchased 100,000 shares at $0.59 on 2024-06-18, increasing his holdings from 380,010 to 480,010 shares (a 26.3% increase in position size). The stock has since declined to $0.57, down 57.8% over the past 90 days and 68.7% from its 52-week high of $1.82, despite Giraudo's prior buy at GOSS on 2023-11-13 returning +54.2% over 90 days. The company is unprofitable, with net income of $-41.9M, yet the CFO has committed to further accumulation at depressed levels. This marks a material insider commitment despite severe price deterioration and negative fundamentals, warranting scrutiny into whether this reflects confidence in a turnaround or execution challenges that the C-suite has not yet publicly disclosed.